AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37409840
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam 0.12 mg kg ‐1 and ketamine 2 mg kg ‐1 (MK group)
Trial: 32285126
Drug: Oral cedazuridine/decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cedazuridine/decitabine (100 mg/35 mg)
Trial: 32285126
Drug: IV decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV decitabine (20 mg/m2)
Trial: 33581958
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Group C)
Trial: 32359104
Drug: nalmefene 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalmefene 20 mg
Trial: 39509231
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy
Trial: 39043009
Drug: Treatment
RxNorm normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: 37535775
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection
Trial: 36376887
Drug: Betaine 100
RxNorm normalized name: betaine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine 100 mg/kg/day
Trial: 32251641
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg P2-VP8 vaccine
Trial: 32251641
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg P2-VP8 vaccine
Trial: 32251641
Drug: 90 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 μg P2-VP8 vaccine
Trial: 35829751
Drug: Peak heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak heart rate prediction equation based on resting HR, presence of diabetes, physical dysfunction (gait speed < 1.0 m/s), and hypoalbuminemia (< 3.5 g/dL)
Trial: 38937792
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment
Trial: 33705168
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (Coping Cat)
Trial: 33999939
Drug: 500 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg.kg‐1 BM sodium citrate ingested over 15 min
Trial: 33999939
Drug: 500 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg.kg‐1 BM sodium citrate ingested over 45 min
Trial: 35451391
Drug: 0.2 μg/(kg·h)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg/(kg·h) of dexmedetomidine
Trial: 35451391
Drug: 0.3 μg/(kg·h)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 μg/(kg·h) of dexmedetomidine
Trial: 35451391
Drug: 0.4 μg/(kg·h)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 μg/(kg·h) of dexmedetomidine
Trial: 35917052
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine therapy (NET) for 4 months before surgery
Trial: 35568822
Drug: Intratracheal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal dexmedetomidine (1 µg/kg) combined with 0.8% ropivacaine (40 mg)
Trial: 35568822
Drug: Intratracheal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal dexmedetomidine (1 µg/kg)
Trial: 36469298
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg/day for 28 days
Trial: 36469298
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT) through naso-duodenal tube, daily for seven days
Trial: 39188940
Drug: Face-to-face treatment
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face treatment
Trial: 34285005
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg once daily) + Exenatide QW (2 mg once weekly)
Trial: 36811901
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg once daily)
Trial: 34285005
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo tablet and sham injection)
Trial: 32958014
Drug: AP 50
RxNorm normalized name: Mapap 500mg Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP 50 µmol/l
Trial: 32958014
Drug: nab-P 5
RxNorm normalized name: Adenosine-5'P
DrugBank: Adenosine phosphate (DB00131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-P 5 µmol/l + AP 10 µmol/l
Trial: 32958014
Drug: nab-P 20
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-P 20 mg/kg + AP 150 mg/kg
Trial: 32958014
Drug: nab-P 18
RxNorm normalized name: 1,8-epoxy-p-menthane
DrugBank: Eucalyptol (DB03852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-P 18 mg/kg + AP 150 mg/kg
Trial: 32958014
Drug: nab-P 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-P 16 mg/kg + AP 150 mg/kg
Trial: 32958014
Drug: Reduced doses
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced doses of nab-P
Trial: 35505441
Drug: 5‐mg/mL EGCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐mg/mL EGCG solution
Trial: 35505441
Drug: Routine periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine periodontal therapy (Control)
Trial: 37857291
Drug: Topiramate monotherapy
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate monotherapy
Trial: 38555718
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2)
Trial: 32788190
Drug: HPV vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine, Gardasil 9
Trial: 32788190
Drug: Placebo hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo hepatitis A vaccine, Avaxim
Trial: 35906874
Drug: Micronutrient-fortified balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient-fortified balanced energy-protein (BEP) supplement and iron-folic acid (IFA) tablet
Trial: 35906874
Drug: Iron-folic acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-folic acid (IFA) tablet
Trial: 33779698
Drug: Ponesimod (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod (20 mg once daily)
Trial: 36001711
Drug: Teriflunomide (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide (14 mg once daily)
Trial: 34195864
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control arm)
Trial: 33017565
Drug: Early Physical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Physical Therapy (EPT)
Trial: 34214479
Drug: Imatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (400 mg, 4 × 100 mg film‐coated tablets per day for 26 weeks)
Trial: 616382680
Drug: Gepotidacin 750
RxNorm normalized name: gepotidacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin 750 mg intravenous every 12 hours (q12h)
Trial: 616382680
Drug: Gepotidacin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin 1,000 mg intravenous every 8 hours (q8h)
Trial: 616382680
Drug: Gepotidacin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin 1,000 mg intravenous every 12 hours (q12h)
Trial: 37349841
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg
Trial: 33340245
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg
Trial: 34980410
Drug: Human safety
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human safety claims (with 'Antibiotic‐free' and 'Pathogen‐ and zoonosis‐free')
Trial: 36001840
Drug: Perioperative IV
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative IV TA alone and post‐operative oral TA (n=26)
Trial: 36001840
Drug: Perioperative IV
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative IV TA plus 48 hours additional oral placebo (n=24)
Trial: 34507703
Drug: LED phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LED phototherapy (630 nm and 940 nm) at a dose of 6 J/cm2, three times a week for 8 weeks
Trial: 34507703
Drug: LED phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LED phototherapy (630 nm and 940 nm) at a dose of 8 J/cm2, three times a week for 8 weeks
Trial: 34507703
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group) consisting of cleaning with physiological solution and alginate hydrogel dressing, daily for 8 weeks
Trial: 35114151
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy only
Trial: 34438361
Drug: 14 mg
RxNorm normalized name: iodine 0.14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg saffron extract (affron®)
Trial: 34460973
Drug: Pregabalin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (75 mg daily)
Trial: 38421679
Drug: PRP injection
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP injection
Trial: 34259904
Drug: Theophylline as
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline as an add-on to thrombolytic therapy
Trial: 34259904
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as an add-on to thrombolytic therapy
Trial: 33407269
Drug: 0.4 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 ml/kg Formulaid™ (100 mg/kg of ARA and 50 mg/kg of DHA)
Trial: 33407269
Drug: 0.4 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 ml/kg MCT‐oil™ (medium chain triglycerides)
Trial: 32111230
Drug: 4% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% albumin solution
Trial: 35852528
Drug: Ringer acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer acetate solution
Trial: 34444817
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of CoQ10 and 20 mg of NADH once daily
Trial: 33728845
Drug: Psychiatric rehabilitation
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric rehabilitation along with standard pharmacological treatment
Trial: 32412900
Drug: Bifidobacterium triple
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium triple viable capsule therapy
Trial: 32412900
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low-fat diet and Bifidobacterium triple viable capsule therapy
Trial: 33892641
Drug: Galcanezumab 120
RxNorm normalized name: Galcanezumab 120 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab 120 mg/month (240 mg loading dose)
Trial: 38683479
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg biweekly
Trial: 34054112
Drug: risperidone 4
RxNorm normalized name: risperidone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone 4 mg
Trial: 34932102
Drug: 60 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 µg RSVpreF
Trial: 34932102
Drug: 120 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 µg RSVpreF
Trial: 34932102
Drug: 240 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 µg RSVpreF
Trial: 34508805
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy responders (n = 21)
Trial: 34508805
Drug: Psychoeducation/supportive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation/supportive therapy responders (n = 6)
Trial: 33892670
Drug: PDLASTA® (Pegfilgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDLASTA® (Pegfilgrastim) - single subcutaneous dose
Trial: 33892670
Drug: PDGRASTIM® (Filgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDGRASTIM® (Filgrastim) - repeated six daily injections
Trial: 35055694
Drug: 20% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% glucose administered orally
Trial: 36317518
Drug: Tegoprazan (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (50, 100, or 200 mg)
Trial: 35191923
Drug: Invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive strategy group (n=124): mechanical compression, intra-arrest transport to a cardiac center for ECPR and immediate invasive assessment and treatment.
Trial: 35577874
Drug: Exercise Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise Therapy (ET)
Trial: 35760493
Drug: Open-label treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label treatment with Enterosgel
Trial: 33300323
Drug: Conventional remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional remifentanil administration
Trial: 33277980
Drug: Fosaprepitant dimeglumine
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosaprepitant dimeglumine (FD) intravenously administered (test group)
Trial: 33277980
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (FD) intravenously administered (reference group)
Trial: 35950949
Drug: Three-monthly viral
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-monthly viral load (VL) testing with additional drug exposure and drug resistance testing in case of viral rebound.
Trial: 35950949
Drug: Three-monthly VL
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-monthly VL testing.
Trial: 34794285
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) plus UDCA
Trial: 38724947
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO)
Trial: 35244287
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose rFSH (0.5 IU/kg/d)
Trial: 35244287
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose rFSH (1.1 IU/kg/d)
Trial: 35244287
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rFSH (2.2 IU/kg/d)
Trial: 35788868
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual control condition (n=110)
Trial: 33637048
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) treatment
Trial: 35943883
Drug: Riboflavin 50
RxNorm normalized name: riboflavin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin 50 mg/d
Trial: 33580297
Drug: β‐d‐glucan‐enriched mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐d‐glucan‐enriched mixture (10.4 g/day) from Lentinula edodes
Trial: 33580297
Drug: Placebo incorporated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo incorporated in three different commercial creams
Trial: 35997978
Drug: Edoxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (15 mg daily)
Trial: 35821512
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT), 40 sessions daily
Trial: 33021146
Drug: Application to
RxNorm normalized name: Embeline 0.05% Scalp Application Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application to track daily walking steps and interact via text messages with group members for 4 weeks
Trial: 32822286
Drug: Binimetinib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib (45 mg twice daily)
Trial: 32822286
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice chemotherapy (PCC)
Trial: 32854231
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment for 3 months
Trial: 32302009
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin
Trial: 34064493
Drug: Prednisone and
RxNorm normalized name: chloroprednisone and antiinfectives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone and antibiotherapy with surgical periodontal therapy
Trial: 37805024
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (control group)
Trial: 33885041
Drug: Pharmacologic prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic prophylaxis (low molecular weight heparin)
Trial: 33885041
Drug: Pharmacologic prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic prophylaxis (unfractionated heparin)
Trial: 34259402
Drug: Intradermal needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal needling combined with heat-sensitive moxibustion
Trial: 34259402
Drug: Opioids according
RxNorm normalized name: clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opioids according to the three-step analgesic method of WHO
Trial: 34369941
Drug: IANB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IANB plus buccal infiltration (1.8 mL IANB + 1.8 mL buccal infiltration)
Trial: 34369941
Drug: IANB (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IANB (3.6 mL)
Trial: 34369941
Drug: IANB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IANB plus lingual infiltration (1.8 mL IANB + 1.8 mL lingual infiltration)
Trial: 33687747
Drug: Molecularly guided
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecularly guided therapy
Trial: 36330105
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30 (BIAsp 30)
Trial: 37863366
Drug: Specialist Depression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialist Depression Service (SDS) offering collaborative treatment with cognitive behavioural therapy (CBT) and pharmacotherapy for 12 months
Trial: 32996139
Drug: Antenatal exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal exercise program including pelvic floor muscle training (12-week standardized program with once weekly group classes and twice weekly home sessions)
Trial: 34774360
Drug: Adjuvanted (AD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted (AD) vaccine
Trial: 33295693
Drug: Conventional ACT
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ACT (200 µg of inhaled salbutamol only)
Trial: 37966817
Drug: Tafamidis 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis 80 mg
Trial: 33070419
Drug: Tafamidis 20
RxNorm normalized name: TAFAMIDIS 20MG TAB UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis 20 mg
Trial: 33220323
Drug: Pooled Tafamidis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled Tafamidis (80 mg and 20 mg)
Trial: 32616003
Drug: 3.5 mm
RxNorm normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mm metallic screw (static implant)
Trial: 32645234
Drug: Large volume
RxNorm normalized name: NEBULIZER,LARGE VOLUME #1770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large volume transfusion (20 mL/kg)
Trial: 32645234
Drug: Standard volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard volume transfusion (15 mL/kg)
Trial: 38350047
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no adjuvant chemotherapy)
Trial: 35338577
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy intervention for renal fatigue
Trial: 34413064
Drug: Immediate endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate endovascular treatment
Trial: 34413064
Drug: Participants who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who personally performed >100 endovascular treatments per year